Esomeprazole

證據等級: L5

預測適應症: 3 個

One-Sentence Summary

Esomeprazole is a proton pump inhibitor (PPI), originally used for acid-related gastrointestinal disorders such as GERD, erosive esophagitis, and peptic ulcer disease. The TxGNN model predicts it may be effective for Duodenogastric Reflux, with 0 clinical trials and 1 publication currently supporting this direction — the evidence base remains preliminary.

Quick Overview

Item	Content
Original Indication	Acid-related GI disorders (GERD, erosive esophagitis, peptic ulcer disease, H. pylori eradication) — inferred from supporting literature; no Norway licence text available (drug not marketed)
Predicted New Indication	Duodenogastric Reflux
TxGNN Prediction Score	99.53%
Evidence Level	L4
Norway Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (data gap). Based on known information, esomeprazole is the S-isomer of omeprazole and belongs to the proton pump inhibitor (PPI) class, which irreversibly inhibits the H⁺/K⁺-ATPase in gastric parietal cells to suppress acid secretion. Its efficacy in acid-related gastrointestinal disorders is well established.

Duodenogastric reflux (DGR) and the drug's original indications share overlapping anatomy and patient populations — both involve upper GI mucosal injury, and DGR frequently co-occurs with, or follows, conditions like GERD or post-gastric-surgery states where PPIs are already used. However, the mechanistic link is indirect: DGR is primarily driven by bile and pancreatic enzyme reflux, not gastric acid itself. Esomeprazole can only reduce the acidic component's synergistic damage to the mucosa when mixed with refluxate — it does not block the root cause of bile reflux. This makes the rationale plausible but partial, consistent with the L4 (mechanism-only) evidence level and "Hold" recommendation currently assigned.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
18679668	2008	Review	European Journal of Clinical Pharmacology	General review of PPI clinical use and pharmacokinetics (peptic ulcer, H. pylori, GERD, NSAID-induced GI lesions, Zollinger-Ellison syndrome); does not directly address duodenogastric reflux as a treatment target

Norway Market Information

Esomeprazole is currently not marketed in Norway (0 authorizations on record), so no local product/label information is available for this evaluation.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence for duodenogastric reflux specifically is limited to a single general PPI review article with no supporting clinical trials, and the mechanistic link is indirect (addresses only the acidic component of a predominantly bile-driven condition). This does not meet the bar to proceed.

Note: This evidence pack also scores esomeprazole against two related indications — duodenal obstruction (L5, no supporting data, mechanistically weak) and duodenal ulcer (L1, extensive trial and literature support). The duodenal ulcer signal is strong, but it reflects an already-established PPI/H. pylori-eradication indication rather than a genuinely novel repurposing use, so it does not change the Hold decision for the duodenogastric reflux candidate evaluated here.

To proceed, the following is needed:

TFDA/Norway package insert warnings and contraindications (blocking data gap, DG001)
Confirmed mechanism of action data from DrugBank (DG002)
Dedicated clinical evidence (preclinical or clinical) evaluating esomeprazole specifically for duodenogastric reflux, ideally with bile-reflux–relevant endpoints
Route of administration compatibility assessment for the new indication
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.